The NECT Story
About Sleeping Sickness
NECT: Contributions to Its Success
ANECT: Other Studies
HAT Regional Network
NECT: challenges in The Field
Patient’s Story
Sailing Away
Brief News
DND<em>i</em>’s HAT-Related News

ASAQ Obtains WHO Prequalification
Sanofi-aventis and DNDi welcome on 16 October 2008 the approval by the World Health Organization (WHO) Prequalification of Medicines Program of Coarsucam™/Artesunate Amodiaquine Winthrop® (ASAQ). ASAQ is the first antimalarial, fixed-dose combination with a soluble formulation, specifically designed for children, to be granted a “prequalified” status. The WHO Prequalification Program aims to make quality priority medicines available in the fields of HIV/AIDS, malaria, tuberculosis, and reproductive health. Products found to live up to the WHO quality standards are included in a "prequalified list" of products. This list, initially intended for procurement of medicines by United Nations agencies, has now become a vital tool for many agencies and organisations involved in bulk purchasing of medicines.
see also
See also:
Published by Drugs for Neglected Diseases Initiative - 15 Chemin Louis-Dunant 1202 Geneva Switzerland - Photo credits: DNDi unless otherwise stated - Editor: Sadia Kaenzig - Tel: +41 22 906 9230 - Fax: +41 22 906 9231 -